Publications by authors named "Arnold Schmidt"
Article Synopsis
- The interaction between CD40L and CD40 plays a crucial role in inflammation related to atherosclerosis, with elevated levels of soluble CD40L (sCD40L) linked to increased cardiovascular risk.
- Recent research investigates the impact of the drug rosiglitazone, a PPARgamma-activating thiazolidinedione, on sCD40L levels in patients with type 2 diabetes and coronary artery disease (CAD) through a randomized trial.
- Findings indicate that rosiglitazone significantly lowers sCD40L levels over 12 weeks, suggesting potential anti-inflammatory benefits and support for its use in reducing cardiovascular risk in at-risk patients.
Background: Matrix metalloproteinases (MMPs) are critically involved in the development of unstable plaques. Although arteriosclerotic lesions in patients with diabetes mellitus are more unstable than those of nondiabetic subjects, nothing is known about serum levels of MMPs in these patients or about mechanisms to modulate MMP levels. We investigated MMP levels in diabetic and nondiabetic coronary artery disease (CAD) patients and performed a clinical trial to assess the effect of the PPARgamma-activating, antidiabetic thiazolidinedione rosiglitazone on MMP levels in diabetic CAD patients.
View Article and Find Full Text PDF